Dupixent vs Tremfya
A side-by-side look at two autoimmune medications advertised on TV. Informational only — not medical advice.
| US Dupixent | US Tremfya | |
|---|---|---|
| Generic name | dupilumab | guselkumab |
| Drug class | IL-4/IL-13 Inhibitor (Biologic) | IL-23 Inhibitor (Biologic) |
| Treats | Eczema, asthma, nasal polyps | Plaque psoriasis, psoriatic arthritis |
| Category | Autoimmune | Autoimmune |
| Manufacturer | Sanofi/Regeneron | Janssen |
| Year approved | 2017 | 2017 |
| FDA warning | No boxed warning | Moderate warnings |
| Est. TV ad spend | $390M | $140M |
| Common side effects | Injection site reactions, Eye inflammation (conjunctivitis), Cold sores, Eosinophilia | Respiratory infections, Headache, Injection site reactions, Joint pain |
Frequently asked questions
Is Dupixent or Tremfya better?
Neither is universally "better." Dupixent (dupilumab) and Tremfya (guselkumab) are both used for autoimmune, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Dupixent and Tremfya?
Dupixent is a IL-4/IL-13 Inhibitor (Biologic) made by Sanofi/Regeneron, while Tremfya is a IL-23 Inhibitor (Biologic) made by Janssen. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Dupixent has the larger estimated TV advertising budget of the two.